- Home
- / Spero Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Spero Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$1.3
2024-10-29
Market Capitalization
$70.8 M
2024-10-29
Revenue
$103.8 M
FY, 2023
CreditSafe Score
?
Score changed on Dec 02, 2024
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|---|
| Revenue | 4.0M | 18.1M | 9.3M | 18.3M | 53.5M | 103.8M | |
| General and administrative expense | 10.8M | 12.9M | 15.6M | 21.4M | 41.7M | 36.5M | 25.6M |
| Operating expense total | 43.7M | 46.8M | 81.4M | 88.4M | 84.1M | ||
| EBIT | (41.7M) | (42.8M) | (63.2M) | (79.1M) | (88.0M) | (42.2M) | 21.5M |
| EBIT margin, % | -1079.3% | -348.4% | -847.9% | -78.9% | |||
| Interest income | 1.3M | 401.0K | 346.0K | 1.1M | 3.9M | ||
| Interest expense | 303.0K | 1.1M | |||||
| Pre tax profit | (39.9M) | (41.7M) | (60.9M) | (78.3M) | (89.8M) | (46.4M) | 25.4M |
| Income tax expense | 2.6M | ||||||
| Net Income | (38.7M) | (41.7M) | (60.9M) | (78.3M) | (89.8M) | (46.4M) | 22.8M |
| EPS | (1.2) |